NCT00006101View on ClinicalTrials.gov

Eflornithine in Treating Patients At High Risk of Developing Prostate Cancer

PHASE2CompletedINTERVENTIONAL
Enrollment

76

Participants

Timeline

Start Date

October 31, 1998

Primary Completion Date

December 31, 2012

Study Completion Date

December 31, 2012

Conditions
Prostate Cancer
Interventions
DRUG

eflornithine

Take 500mg of DFMO per day for 12 months

DRUG

Placebo

Take placebo per day for 12 months

Trial Locations (1)

92868

Chao Family Comprehensive Cancer Center at University of California Irvine Cancer Center, Orange

All Listed Sponsors
collaborator

National Cancer Institute (NCI)

NIH

lead

Thomas E. Ahlering

OTHER

NCT00006101 - Eflornithine in Treating Patients At High Risk of Developing Prostate Cancer | Biotech Hunter | Biotech Hunter